Antalarmin blockade of corticotropin releasing hormone-induced hypertension in rats

Richard J. Briscoe, Camilo L. Cabrera, Theodore J. Baird, Kenner C. Rice, James H. Woods

Research output: Contribution to journalArticlepeer-review

45 Scopus citations


Central administration of CRH results in endocrinological, cardiovascular, and behavioral effects that suggest stress or anxiety. Among these is a marked pressor response. Parenteral administration of CRH, however, results in hypotension. We used parenteral administration of antalarmin, a novel, small molecule CRH1 receptor antagonist, and α-helical CRH9-41, a peptidic CRHR1/CRHR2 antagonist to attempt to determine the receptor mechanisms through which CRH is acting in both of these situations. Our results suggest that the hypertension produced by central CRH administration is mediated through central CRHR1 receptors, whereas the hypotension produced by parenteral CRH administration is mediated through peripheral CRHR2 receptors. Copyright (C) 2000 Elsevier Science B.V.

Original languageEnglish (US)
Pages (from-to)204-207
Number of pages4
JournalBrain Research
Issue number2
StatePublished - Oct 27 2000
Externally publishedYes


  • Antalarmin
  • Blood pressure
  • Corticotropin releasing hormone
  • Corticotropin releasing hormone antagonist
  • Rat
  • α-helical CRH

ASJC Scopus subject areas

  • Neuroscience(all)
  • Molecular Biology
  • Clinical Neurology
  • Developmental Biology


Dive into the research topics of 'Antalarmin blockade of corticotropin releasing hormone-induced hypertension in rats'. Together they form a unique fingerprint.

Cite this